Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Type 2 Diabetes: TRANSCEND-T2D-1 In March 2026, Eli Lilly published topline results from TRANSCEND-T2D-1 the Phase 3 trial of retatrutide in adults with type 2 diabetes
A recent head-to-head trial of the peptide drugs found that Lillys tirzepatide, which targets both GLP-1 and GIP receptors, produced greater average weight reductions than Novos semaglutide which targets only GLP-1
Gaelikine's GLP-1 Modulation Supplement stands out in the crowded wellness market for its unique approach to appetite regulation and overall health optimization
For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly
Researchers looking to include MT1 and/or MT2 in their studies are encouraged to visit our top recommended peptide vendor for quality peptides at unbeatable prices.
US$ 26.54
US$ 25.09
US$ 21.91
